Placental Mesenchymal Stem Cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Placental Mesenchymal Stem Cells
Accession Number
DB15730
Description

The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs). It can be obtained relatively easily as medical waste from which MSCs can be non-invasively extracted and without the ethical issues that come with embryonic stem cells. The placental MSCs (pMSCs) are obtained from either the fetal side, which hold chorionic plate-derived MSCs, or the maternal side, which contributes decidual parietalis-dreived MSCs. Although pMSCs have multi-lineage differentiation potential, the fetal-side pMSCs have greater expansion capacity, proliferation and differentiation potential than maternal-side pMSCs. It was also found that fetal-side pMSCs express different surface markers.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • Placental mesenchymal stromal cells
  • PLX-PAD
External IDs
  • Placental Mesenchymal Stem Cells

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

All pMSCs contain therapeutic potential and have been used in medical treatment already as they are an ideal candidate for allogeneic transplantation due to their immunomodulatory properties and low immunogenicity. MSCs secrete growth factors and cytokines during angiogenesis, anti-fibrotic processes, chemotaxis, hematopoiesis induction, immunomodulation, and inhibition of apoptosis, with different levels of secretion between fetal- vs. maternal-side pMSCs. Fetal-side pMSCs secrete a higher level of HGF and VCAM-1 and hold potential in angiogenic therapy, while maternal-side pMSCs have the potential for treatment of critical limb ischemia as they secrete VEGF and Ang-1.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Wu M, Zhang R, Zou Q, Chen Y, Zhou M, Li X, Ran R, Chen Q: Comparison of the Biological Characteristics of Mesenchymal Stem Cells Derived from the Human Placenta and Umbilical Cord. Sci Rep. 2018 Mar 22;8(1):5014. doi: 10.1038/s41598-018-23396-1. [PubMed:29568084]
  2. Papait A, Vertua E, Magatti M, Ceccariglia S, De Munari S, Silini AR, Sheleg M, Ofir R, Parolini O: Mesenchymal Stromal Cells from Fetal and Maternal Placenta Possess Key Similarities and Differences: Potential Implications for Their Applications in Regenerative Medicine. Cells. 2020 Jan 6;9(1). pii: cells9010127. doi: 10.3390/cells9010127. [PubMed:31935836]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentCritical Limb Ischemia (CLI)1
3RecruitingTreatmentHip Fracture1
2CompletedTreatmentIntermittent Claudication / Peripheral Artery Disease (PAD)1
2RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS) / COVID / COVID - 19 / Novel Coronavirus Infectious Disease (COVID-19)1
1CompletedTreatmentCritical Limb Ischemia (CLI) / Peripheral Artery Disease (PAD) / Peripheral Vascular Disease Patient2
1TerminatedTreatmentPulmonary Arterial Hypertension (PAH)1
1, 2CompletedTreatmentMuscle Injuries / Total Hip Arthroplasty (THA)1
Not AvailableAvailableNot AvailableCritical Limb Ischemia (CLI)2
Not AvailableNot Yet RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS) / Novel Coronavirus Infectious Disease (COVID-19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 13:12 / Updated on August 13, 2020 01:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates